Alzheimer's Disease Trial, Not Yet Recruiting NCT07529015 Sponsor: Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida) Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Not Yet Recruiting

NCT07529015
Not Yet Recruiting Not Applicable

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • People who have been diagnosed with amnestic Mild Cognitive Impairment (a type of early memory difficulty) using recognised international guidelines, and who have a positive result on a specific blood test measuring a protein linked to Alzheimer's disease (called plasma p-tau217).
  • People who have been diagnosed with amnestic Mild Cognitive Impairment using recognised international guidelines, and who have a negative result on the plasma p-tau217 blood test (for the comparison group in this trial).
  • Older adults aged 65 or over who have no thinking or memory problems, score 28 or higher on a standard memory and thinking test (the Mini-Mental State Examination), and have a negative result on the plasma p-tau217 blood test.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • People who have been diagnosed with dementia caused by Alzheimer's disease or any other type of dementia.
  • People who have a diagnosed sleep disorder, such as narcolepsy, severe insomnia, severe obstructive sleep apnea (where breathing repeatedly stops during sleep), or severe ongoing lack of sleep.
  • People who have hearing problems.
  • People who are unable to read or write.
  • People who have certain serious health conditions, including cancer, severe depression, severe kidney or liver disease, a history of seizures, or severe heart or breathing failure.
  • People with a history of alcohol or substance misuse.
  • People whose brain scan (MRI) shows evidence of a stroke, fluid build-up in the brain, a growth or mass, or any other significant brain or nervous system disease.
  • People who have a vitamin B12 or folate deficiency that has not been treated, or has only been treated for less than 3 months before the screening visit.
  • People who have a thyroid condition that has not been treated.
  • People who have used certain medications — including beta-blockers, antidepressants, antipsychotics, or sleeping tablets — within 15 days before a sleep study test called polysomnography.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 12 August 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +34-973702413

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Institut de Recerca Biomèdica de Lleida-Fundació Dr. Pifarré (IRBLleida)
Registry
ClinicalTrials.gov
Start date
1 April 2026
Est. completion
1 September 2027

Where this trial is recruiting

🇪🇸 Spain

Primary endpoints

Impact on SWS: SO and sleep spindle density; Impact on SWS: SO and sleep spindle duration; Impact on SWS: SO and sleep spindle peak-to-peak amplitude; Impact on SWS: SO and sleep spindle peak power frequency; Impact on SWS: SO and sleep spindle power; Impact on declarative memory consolidation: correct performance in the Verbal Paired Associates test; Impact on procedural memory consolidation: correct performance in the Motor Sequence Typing task; Impact on procedural memory consolidation: incorrect performance in the Motor Sequence Typing task; Impact on procedural memory consolidation: total...

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 12 August 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov